



Entegris Earnings Summary

Second Quarter 2026
August 4, 2026

Safe Harbor

This presentation contains “forward-looking statements”. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “should,” “may,” “will,” “would” or the negative thereof and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on current management expectations and assumptions only as of the date of this Quarterly Report. They are not guarantees of future performance and they involve substantial risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, but are not limited to, fluctuations in the demand for semiconductors and the overall volume of semiconductor manufacturing; the impact of global economic uncertainty, including financial market volatility, which may result in lower consumer spending, inflationary pressures, a higher interest rate environment, an economic recession, and bank instability; supply chain interruptions and the Company’s dependence on sole, single, and limited source suppliers and related raw material shortages and cost increases; operational, political, legal and other risks associated with the Company’s international operations, including challenges in hiring and integrating workers in different countries, maintaining appropriate business practices across the varied jurisdictions in which we operate, and engaging and managing global, regional and local third-party service providers; risks related to geopolitical uncertainty and regional and global instabilities and hostilities, including, but not limited to, the ongoing conflicts between Ukraine and Russia, and conflicts in the Middle East, as well as the global responses thereto; export controls, economic sanctions, and similar restrictions; the concentration and consolidation of the Company’s customer base; the Company’s ability to meet rapid demand shifts; the Company’s ability to continue technological innovation and to introduce new products to meet customers’ rapidly changing requirements; manufacturing and other operational disruptions or delays; IT system failures, network disruptions, and cybersecurity risks; tariffs, additional taxes and other protectionist measures resulting from international trade disputes, strained international relations and changes in foreign and national security policy; the risks associated with the use and manufacture of hazardous materials; goodwill impairment; challenges in attracting and retaining qualified personnel; the Company’s ability to protect and enforce intellectual property rights; artificial intelligence; the Company’s environmental, social, and governance commitments; legal and regulatory risks, including changes in laws and regulations related to the environment, health and safety, accounting standards, and corporate governance, across the jurisdictions in which the Company operates; changes in taxation or adverse tax rulings; the ability to obtain government incentives and the possibility that competitors will benefit from government incentives for which the Company does not qualify; the amount and consequences of the Company’s indebtedness, the Company’s ability to repay its debt and to obtain future financing, and the Company’s obligations under its current outstanding credit facilities; volatility in the Company’s stock price; the payment of cash dividends and the adoption of future share repurchase programs; the Company’s ability to effectively implement any organizational changes; substantial competition; the Company’s ability to identify, complete and integrate acquisitions, joint ventures, divestitures or other similar transactions; the impacts of climate change; and other matters. These risks and uncertainties also include, but are not limited to, the risk factors and additional information described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on February 11, 2026, including under the heading “Risk Factors” in Item 1A, and in the Company’s other periodic filings with the SEC. Except as required under the federal securities laws and the rules and regulations of the SEC, the Company undertakes no obligation to update any forward-looking statements or information contained herein, which speak as of their respective dates.

This presentation contains references to “Adjusted Net Sales”, “Adjusted EBITDA,” “Adjusted EBITDA – as a % of Net Sales,” “Adjusted Operating Income,” “Adjusted Operating Margin,” “Adjusted Gross Profit,” “Adjusted Gross Margin – as a % of Net Sales,” “Adjusted Segment Profit,” “Adjusted Segment Profit Margin,” “Non-GAAP Operating Expenses,” “Non-GAAP Tax Rate,” “Non-GAAP Net Income,” “Diluted Non-GAAP Earnings per Common Share,” “Free Cash Flow,” and other measures that are not presented in accordance with GAAP. The non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures but should instead be read in conjunction with the GAAP financial measures. Further information with respect to and reconciliations of such measures to the most directly comparable GAAP measure can be found attached to this presentation.

Summary – Consolidated Statement of Operations GAAP

\$ in millions, except per share data	2Q26	2Q25	1Q26	2Q26 over 2Q25	2Q26 over 1Q26
Net Sales	\$883.2	\$792.4	\$811.9	11.5%	8.8%
Gross Margin	47.6%	44.4%	46.9%		
Operating Expenses	\$255.4	\$245.4	\$239.2	4.1%	6.8%
Operating Income	\$164.6	\$106.1	\$141.6	55.1%	16.2%
Operating Margin	18.6%	13.4%	17.4%		
Tax Rate	15.0%	5.0%	1.1%		
Net Income	\$93.6	\$52.8	\$92.0	77.3%	1.7%
Diluted Earnings Per Common Share	\$0.61	\$0.35	\$0.60	74.3%	1.7%

Summary – Consolidated Statement of Operations Non-GAAP¹

\$ in millions, except per share data	2Q26	2Q25	1Q26	2Q26 over 2Q25	2Q26 over 1Q26
Net Sales	\$883.2	\$792.4	\$811.9	11.5%	8.8%
Adjusted Gross Margin – as a % of Net Sales ²	47.6%	44.6%	46.9%		
Non-GAAP Operating Expenses ³	\$203.9	\$188.2	\$189.1	8.3%	7.8%
Adjusted Operating Income	\$216.3	\$165.4	\$192.0	30.8%	12.7%
Adjusted Operating Margin	24.5%	20.9%	23.6%		
Non-GAAP Tax Rate ⁴	16.2%	12.5%	7.9%		
Non-GAAP Net Income ⁵	\$142.7	\$100.6	\$132.5	41.8%	7.7%
Diluted Non-GAAP Earnings Per Common Share	\$0.93	\$0.66	\$0.86	40.9%	8.1%
Adjusted EBITDA	\$250.7	\$216.7	\$226.1	15.7%	10.9%
Adjusted EBITDA – as a % of Net Sales	28.4%	27.3%	27.8%		

1. See GAAP to non-GAAP reconciliation tables in the appendix of this presentation. 2. Excludes restructuring costs. 3. Excludes amortization expense and restructuring costs. 4. Reflects the tax effect of non-GAAP adjustments and discrete tax items to GAAP taxes. 5. Excludes the items noted in footnotes 2 and 3, equity investment impairment and loss on extinguishment of debt in 2026.

2Q26 Segment Highlights

Materials Solutions (MS)

\$ in millions	2Q26	2Q25	1Q26	2Q26 over 2Q25	2Q26 over 1Q26
Net Sales	\$371.3	\$354.9	\$351.1	4.6%	5.8%
Segment Profit	\$77.7	\$72.5	\$75.9	7.2%	2.4%
Segment Profit Margin	20.9%	20.4%	21.6%		
Adj. Segment Profit ¹	\$77.7	\$75.5	\$77.1	2.9%	0.8%
Adj. Segment Profit Margin ¹	20.9%	21.3%	22.0%		

Advanced Purity Solutions (APS)

\$ in millions	2Q26	2Q25	1Q26	2Q26 over 2Q25	2Q26 over 1Q26
Net Sales	\$514.6	\$439.9	\$463.6	17.0%	11.0%
Segment Profit	\$150.9	\$95.9	\$133.6	57.4%	12.9%
Segment Profit Margin	29.3%	21.8%	28.8%		
Adj. Segment Profit ¹	\$155.8	\$105.8	\$135.1	47.3%	15.3%
Adj. Segment Profit Margin ¹	30.3%	24.1%	29.1%		

Summary – Balance Sheet Items

\$ in millions	2Q26		2Q25		1Q26	
	\$ Amount	% Total	\$ Amount	% Total	\$ Amount	% Total
Cash and Cash Equivalents	\$353.6	4.2%	\$376.8	4.5%	\$442.7	5.2%
Accounts Receivable, Net	\$559.1	6.6%	\$494.1	5.8%	\$529.5	6.2%
Inventories, Net	\$703.9	8.4%	\$694.6	8.2%	\$644.4	7.6%
Net PP&E	\$1,624.5	19.3%	\$1,662.3	19.7%	\$1,636.6	19.3%
Total Assets	\$8,418.5		\$8,449.5		\$8,475.1	
Accounts Payable	\$242.8	2.9%	\$156.8	1.9%	\$209.0	2.5%
Other Current Liabilities	\$342.6	4.1%	\$310.4	3.7%	\$346.6	4.1%
Long-Term Debt	\$3,456.0	41.1%	\$3,987.8	47.2%	\$3,651.2	43.1%
Total Liabilities	\$4,262.3	50.6%	\$4,640.4	54.9%	\$4,425.9	52.2%
Total Shareholders' Equity	\$4,156.2	49.4%	\$3,809.1	45.1%	\$4,049.2	47.8%

Summary – Cash Flows

\$ in millions	2Q26	2Q25	1Q26
Beginning Cash Balance	\$442.7	\$340.9	\$360.4
Cash provided by operating activities	156.2	113.5	183.0
Capital expenditures	(39.3)	(66.5)	(41.5)
Proceeds from government incentives	3.4	—	2.0
Other investing activities	(0.3)	(0.1)	1.1
Net payments on debt	(200.0)	—	(50.0)
Payments for dividends	(15.4)	(15.2)	(15.4)
Other financing activities	6.9	(2.6)	3.8
Effect of exchange rates	(0.6)	6.8	(0.7)
Ending Cash Balance	\$353.6	\$376.8	\$442.7
Free Cash Flow ¹	120.3	47.0	143.5

Outlook

GAAP

\$ in millions, except share data	3Q26 Guidance	2Q26 Actual	1Q26 Actual
Net Sales	\$905 - \$935	\$883.2	\$811.9
Operating Expenses	\$256 - \$264	\$255.4	\$239.2
Net Income	\$116 - \$128	\$93.6	\$92.0
Diluted Earnings per Common Share	\$0.75 - \$0.83	\$0.61	\$0.60
Operating Margin	19.2% - 20.2%	18.6%	17.4%

Non-GAAP

\$ in millions, except share data	3Q26 Guidance	2Q26 Actual	1Q26 Actual
Net Sales	\$905 - \$935	\$883.2	\$811.9
Non-GAAP Operating Expenses ¹	\$211 - \$219	\$203.9	\$189.1
Non-GAAP Net Income ¹	\$148 - \$160	\$142.7	\$132.5
Diluted non-GAAP Earnings per Common Share ¹	\$0.96 - \$1.04	\$0.93	\$0.86
Adjusted EBITDA Margin ¹	28.0% - 29.0%	28.4%	27.8%



Appendix

Consolidated (as reported) Summary Financials Non-GAAP¹

\$ in millions	1Q25	2Q25	3Q25	4Q25	FY2025	1Q26	2Q26
Net Sales	\$773.2	\$792.4	\$807.1	\$823.9	\$3,196.6	\$811.9	\$883.2
Adjusted Gross Margin %	46.1%	44.6%	43.6%	44.0%	44.6%	46.9%	47.6%
Non-GAAP Operating Expenses	\$185.9	\$188.2	\$181.3	\$187.9	\$743.3	\$189.1	\$203.9
Adjusted Operating Income	\$170.8	\$165.4	\$170.3	\$174.4	\$680.9	\$192.0	\$216.3
Adjusted Operating Margin	22.1%	20.9%	21.1%	21.2%	21.3%	23.6%	24.5%
Adjusted EBITDA	\$220.7	\$216.7	\$220.7	\$228.1	\$886.2	\$226.1	\$250.7
Adjusted EBITDA %	28.5%	27.3%	27.3%	27.7%	27.7%	27.8%	28.4%

Segment (as reported) Financials Non-GAAP¹

\$ in millions	1Q25	2Q25	3Q25	4Q25	FY2025	1Q26	2Q26
Net Sales:							
MS	\$341.4	\$354.9	\$348.6	\$361.8	\$1,406.7	\$351.1	\$371.3
APS	433.9	439.9	460.8	464.5	1,799.1	463.6	514.6
Inter-segment elimination	(2.1)	(2.4)	(2.3)	(2.4)	(9.2)	(2.8)	(2.7)
Total Sales	\$773.2	\$792.4	\$807.1	\$823.9	\$3,196.6	\$811.9	\$883.2
Adjusted Segment Profit:							
MS	\$75.1	\$75.5	\$65.9	\$75.7	\$292.2	\$77.1	\$77.7
APS	110.4	105.8	119.2	115.0	450.4	135.1	155.8
Adjusted Segment Profit Margin:							
MS	22.0%	21.3%	18.9%	20.9%	20.8%	22.0%	20.9%
APS	25.4%	24.1%	25.9%	24.8%	25.0%	29.1%	30.3%

Reconciliation of Gross Profit (as reported) to Adjusted Gross Profit

\$ in millions	1Q25	2Q25	3Q25	4Q25	FY2025	1Q26	2Q26
Net Sales	\$773.2	\$792.4	\$807.1	\$823.9	\$3,196.6	\$811.9	\$883.2
Gross profit - GAAP	\$356.5	\$351.5	\$351.3	\$360.6	\$1,419.9	\$380.8	\$420.0
Adjustments to gross profit:							
Restructuring costs ¹	0.2	2.1	0.3	1.7	4.3	0.3	0.2
Adjusted Gross Profit	\$356.7	\$353.6	\$351.6	\$362.3	\$1,424.2	\$381.1	\$420.2
Gross margin - as a % of net sales	46.1%	44.4%	43.5%	43.8%	44.4%	46.9%	47.6%
Adjusted gross margin - as a % of net sales	46.1%	44.6%	43.6%	44.0%	44.6%	46.9%	47.6%

1. Restructuring charges resulting from discrete cost saving initiatives inclusive of employee termination benefit, contract termination costs and asset impairment charges, primarily related to (i) an internal reorganization, combining two complementary divisions into one and realigning our customer facing organization, (ii) workforce reductions, contract termination costs and the abandonment of certain capital equipment no longer necessary for the Company's long-term objectives and (iii) the wind-down of the Company's Life Sciences Fluid Management business.

Reconciliation of GAAP Operating Expenses (as reported) to Non-GAAP

\$ in millions	1Q25	2Q25	3Q25	4Q25	FY2025	1Q26	2Q26
GAAP Operating Expenses	\$234.2	\$245.4	\$228.7	\$255.7	\$964.0	\$239.2	\$255.4
Adjustments to operating expenses:							
Restructuring costs ¹	2.2	11.2	1.4	10.6	25.4	3.8	5.4
Loss from sale of business ²	—	—	—	10.9	10.9	—	—
Amortization of intangible assets ³	46.1	46.0	46.0	46.3	184.4	46.3	46.1
Non-GAAP operating expenses	\$185.9	\$188.2	\$181.3	\$187.9	\$743.3	\$189.1	\$203.9

1. Restructuring charges resulting from discrete cost saving initiatives inclusive of employee termination benefit, contract termination costs and asset impairment charges, primarily related to (i) an internal reorganization, combining two complementary divisions into one and realigning our customer facing organization, (ii) workforce reductions and (iii) the wind-down of the Company's Life Sciences Fluid Management business. 2. Non-recurring net loss from the sale of a small, industrial specialty chemicals business. 3. Non-cash amortization expense associated with intangibles acquired in acquisitions.

Reconciliation of MS Segment Profit to Adjusted MS Segment Profit Non-GAAP

\$ in millions	1Q25	2Q25	3Q25	4Q25	FY2025	1Q26	2Q26
MS segment profit	\$75.0	\$72.5	\$65.2	\$63.9	\$276.6	\$75.9	\$77.7
Restructuring costs ¹	0.1	3.0	0.7	0.9	4.7	1.2	—
Loss from the sale of business	—	—	—	10.9	10.9	—	—
MS adjusted segment profit	\$75.1	\$75.5	\$65.9	\$75.7	\$292.2	\$77.1	\$77.7

Reconciliation of APS Segment Profit to Adjusted APS Segment Profit Non-GAAP

\$ in millions	1Q25	2Q25	3Q25	4Q25	FY2025	1Q26	2Q26
APS segment profit	\$108.1	\$95.9	\$118.2	\$104.2	\$426.4	\$133.6	\$150.9
Restructuring costs ¹	2.3	9.9	1.0	10.8	24.0	1.5	4.9
APS adjusted segment profit	\$110.4	\$105.8	\$119.2	\$115.0	\$450.4	\$135.1	\$155.8

14 | 1. Restructuring charges resulting from discrete cost saving initiatives inclusive of employee termination benefit, contract termination costs and asset impairment charges, primarily related to (i) an internal reorganization, combining two complementary divisions into one and realigning our customer facing organization, (ii) workforce reductions and (iii) the wind-down of the Company's Life Sciences Fluid Management business.

Reconciliation of GAAP Net Income to Adjusted Operating Income and Adjusted EBITDA

\$ in millions	1Q25	2Q25	3Q25	4Q25	FY2025	1Q26	2Q26
Net Sales	\$773.2	\$792.4	\$807.1	\$823.9	\$3,196.6	\$811.9	\$883.2
Net income	62.9	52.8	70.5	49.4	235.6	92.0	93.6
Net income - as a % of net sales	8.1%	6.7%	8.7%	6.0%	7.4%	11.3%	10.6%
Adjustments to net income:							
Income tax expense	8.2	2.8	1.5	5.5	18.0	1.0	16.5
Interest expense, net	49.6	50.5	46.1	45.7	191.9	47.0	46.7
Other expense (income), net	1.3	(0.2)	4.2	4.1	9.4	1.4	7.8
Equity in net loss of affiliates	0.3	0.2	0.3	0.2	1.0	0.2	0.0
GAAP - Operating income	\$122.3	\$106.1	\$122.6	\$104.9	\$455.9	\$141.6	\$164.6
Operating margin - as a % of net sales	15.8%	13.4%	15.2%	12.7%	14.3%	17.4%	18.6%
Restructuring costs ¹	2.4	13.3	1.7	12.3	29.7	4.1	5.6
Loss from sale of business ²	—	—	—	10.9	10.9	—	—
Amortization of intangible assets ³	46.1	46.0	46.0	46.3	184.4	46.3	46.1
Adjusted operating income	\$170.8	\$165.4	\$170.3	\$174.4	\$680.9	\$192.0	\$216.3
Adjusted operating margin - as a % of net sales	22.1%	20.9%	21.1%	21.2%	21.3%	23.6%	24.5%
Depreciation	49.9	51.3	50.4	53.7	205.3	34.1	34.4
Adjusted EBITDA	\$220.7	\$216.7	\$220.7	\$228.1	\$886.2	\$226.1	\$250.7
Adjusted EBITDA - as a % of net sales	28.5%	27.3%	27.3%	27.7%	27.7%	27.8%	28.4%

1. Restructuring charges resulting from discrete cost saving initiatives inclusive of employee termination benefit, contract termination costs and asset impairment charges, primarily related to (i) an internal reorganization, combining two complementary divisions into one and realigning our customer facing organization, (ii) workforce reductions and (iii) the wind-down of the Company's Life Sciences Fluid Management business. 2.Non-recurring net loss from the sale of a small, industrial specialty chemicals business. 3. Non-cash amortization expense associated with intangibles acquired in acquisitions.

ENTEGRIS SECOND QUARTER 2026 EARNINGS SUMMARY

Reconciliation of GAAP Net Income and Diluted Earnings per Common Share to Non-GAAP Net Income and Diluted Non-GAAP Earnings per Common Share

\$ in millions, except per share data	1Q25	2Q25	3Q25	4Q25	FY2025	1Q26	2Q26
GAAP net income	\$62.9	\$52.8	\$70.5	\$49.4	\$235.6	\$92.0	\$93.6
Restructuring costs ¹	2.4	13.3	1.7	12.3	29.7	4.1	5.6
Equity investment impairment ²	—	—	—	—	—	—	6.7
Loss from the sale of business ³	—	—	—	10.9	10.9	—	—
Amortization of intangible assets ⁴	46.1	46.0	46.0	46.3	184.4	46.3	46.1
Loss on extinguishment of debt ⁵	—	—	1.7	1.5	3.2	0.5	1.7
Tax effect of adjustments to net income and discrete items ⁶	(9.9)	(11.5)	(10.0)	(13.9)	(45.3)	(10.4)	(11.0)
Non-GAAP net income	101.5	100.6	109.9	106.5	418.5	132.5	142.7
Diluted earnings per common share	\$0.41	\$0.35	\$0.46	\$0.32	\$1.55	\$0.60	\$0.61
Effect of adjustments to net income	\$0.25	\$0.31	\$0.26	\$0.37	\$1.20	\$0.26	\$0.32
Diluted non-GAAP earnings per common share	\$0.67	\$0.66	\$0.72	\$0.70	\$2.75	\$0.86	\$0.93
Diluted weighted average shares outstanding	152.0	151.9	152.3	152.5	152.2	153.2	153.6

1. Restructuring charges resulting from discrete cost saving initiatives inclusive of employee termination benefit, contract termination costs and asset impairment charges, primarily related to (i) an internal reorganization, combining two complementary divisions into one and realigning our customer facing organization, (ii) workforce reductions and (iii) the wind-down of the Company's Life Sciences Fluid Management business. 2. Equity investment impairment in 2026. 3. Non-recurring net loss from the sale of a small, industrial specialty chemicals business. 4. Non-cash amortization expense associated with intangibles acquired in acquisitions. 5. Loss on extinguishment of debt of our Term Loan Facility in 2025 and 2026. 6. The tax effect of pre-tax adjustments to net income was calculated using the applicable marginal tax rate for each respective year.

Reconciliation of GAAP Outlook to Non-GAAP Outlook*

\$ in millions	Third Quarter Outlook
Reconciliation GAAP operating expenses to non-GAAP operating expenses:	September 26, 2026
GAAP operating expenses	\$256 - \$264
Adjustments to net income:	
Amortization of intangible assets	45
Non-GAAP operating expenses	\$211 - \$219

\$ in millions	Third Quarter Outlook
Reconciliation GAAP net income to non-GAAP net income:	September 26, 2026
GAAP net income	\$116 - \$128
Adjustments to net income:	
Amortization of intangible assets	45
Income tax effect	(13)
Non-GAAP net income	\$148 - \$160

\$ in millions, except per share data	Third Quarter Outlook
Reconciliation GAAP diluted earnings per share to non-GAAP diluted earnings per share:	September 26, 2026
Diluted earnings per common share	\$0.75 - \$0.83
Adjustments to diluted earnings per common share:	
Amortization of intangible assets	0.29
Income tax effect	(0.08)
Diluted non-GAAP earnings per common share	\$0.96 - \$1.04

Reconciliation of GAAP Outlook to Non-GAAP Outlook* (continued)

\$ in millions	Third Quarter Outlook
Reconciliation GAAP operating income to non-GAAP operating income and adjusted EBITDA:	September 26, 2026
Net sales	\$905 - \$935
GAAP - Operating income	\$174 - \$189
Operating margin - as a % of net sales	19.2% - 20.2%
Restructuring costs	—
Amortization of intangible assets	45
Adjusted operating income	\$219 - \$234
Adjusted operating margin - as a % of net sales	24.2% - 25.1%
Depreciation	34
Adjusted EBITDA	\$253- \$269
Adjusted EBITDA - as a % of net sales	28.0% - 29.0%